MedImmune stays at market perform by JMP

MedImmune, Inc. was reiterated at market perform by JMP Securities analyst Adam Cutler after the company reported first-quarter 2006 results. Total revenue of $498 million missed JMP's estimate of $552 million and the Street consensus estimate of $540 million. However, earnings per share of $0.18 met the analyst's estimate but was still lower than the consensus estimate of $0.27. The shortfall is blamed on lower-than-expected Synagis revenue. Shares of the Gaithersburg, Md., biotechnology company were up 26 cents, or 0.83%, at $31.43 on volume of 7,444,891 shares versus the three-month running average of 2,083,970 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.